Attendee search 

China innovative drug R&D company

Biotech

Top 5 med tech company

Kaitai is a biotech venture fund with about 40 biotech portfolio companies. Kaitai's fund size is about 7 billions dollars. They are positively looking for cutting edge technologies.

国际医疗器械研发及医疗培训

Mitochondria play a central role in metabolic diseases and cancer. Targeting mitochondria for therapeutic development provides a unique opportunity for the effective treatment of these devastating diseases, including nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and various cancers.

Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.

We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.

Top tier equity investment Institute wholly owned by CICC

Creacion Ventures is an USD fund of 150million, set up in 2020, focusing on investing cross border biotech companies. We spin off from 6 Dimensions.